Massachusetts is currently home to 3200 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Smartphone Application for Neurology and Telemedicine
NCT06245174
Recruiting
This observational research study is designed to assess the feasibility of developing a new software application that can be used in the home using a commercially available camera to measure abnormal body movements associated with Parkinson's disease (PD). The goal of this study is to validate the motor outcomes derived from a consumer camera observing a sub-set of standardized assessment tasks with respect to the reference motion capture system.
Gender:
ALL
Ages:
35 years and above
Trial Updated:
07/29/2024
Locations: Altec Inc., Natick, Massachusetts
Conditions: Parkinson Disease(PD)
Register for Updates
TRAQinform Assessment of Immunotherapy Response
NCT05819255
Recruiting
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma
Register for Updates
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580
Recruiting
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
NCT06522880
Recruiting
The goal of STAGE I of the CMV TransmIT Study is to determine the prevalence of CMV shedding in children up to and including 36 months of age in large group childcare centers and in staff who regularly work at the center. Participants will complete a health survey and provide one saliva sample for CMV PCR testing. In addition, infrastructure for the study will be developed (e.g. community engagement to build the network of centers, data pipelines, digital platform, sampling workflows) and partic... Read More
Gender:
ALL
Ages:
Between 1 day and 36 months
Trial Updated:
07/25/2024
Locations: UMass Chan Medical School, Worcester, Massachusetts
Conditions: Cytomegalovirus Infections
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: NECCR Primacare Research, LLC, Fall River, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis
NCT04102371
Recruiting
The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.
Gender:
ALL
Ages:
Between 2 months and 17 years
Trial Updated:
07/25/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Shock, Septic
Register for Updates
Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis
NCT06194123
Recruiting
The objective of this study is to evaluate how well the study product, Crest Daily Whitening Serum, alleviates Xerostomia and perceived halitosis over 1 week of use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Tufts University School of Dental Medicine, Boston, Massachusetts
Conditions: Xerostomia, Halitosis
Register for Updates
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072
Recruiting
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Massachusetts General Hospital Hematology Oncology, Boston, Massachusetts
Conditions: Metastatic Uveal Melanoma
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Virtual Reality Intervention for Fear of Heights
NCT06468878
Recruiting
Exposure-based cognitive behavior therapy is an efficacious treatment for acrophobia (fear of heights) and has been delivered effectively in a virtual reality (VR) environment. The present study is designed to evaluate the effects of liked, non-lyrical background music on the efficacy of a brief VR exposure intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Boston University, Boston, Massachusetts
Conditions: Acrophobia
Register for Updates